EQT Private Equity to sell Schülke, a sustainability leader in infection prevention and treatment for the healthcare industry

• EQT Private Equity to sell Schülke to the ATHOS Consortium, having acquired the Company in a carve-out from Air Liquide in July 2020. The Company has delivered double digit annual revenue growth and almost doubled EBITDA in its core healthcare business over this time
• Under EQT Private Equity's ownership, Schülke has been repositioned to focus entirely on the healthcare and life science market, while expanding into new geographies and sales channels through five add-on acquisitions              
• The Company has also established itself as a sustainability leader, for example by launching a pioneering green hospital-grade product line, transitioning to almost 100% green electricity, and signing up to the Science Based Targets initiative

STOCKHOLM, Aug. 7, 2023 /PRNewswire/ -- EQT is pleased to announce that the EQT VIII fund ("EQT Private Equity") has agreed to sell Schülke (the "Company"), a leading provider of infection prevention and treatment solutions for the healthcare industry, to a consortium led by ATHOS, a Munich-based single family office, along with other co-investors such as Bitburger Holding (the "ATHOS Consortium"). 

Schülke is a key partner to the healthcare industry with an almost 135-year heritage of developing holistic and mission-critical infection prevention and treatment solutions. It supplies hospitals and other healthcare institutions with high quality disinfectants and antisepsis products. It also sells to the pharmacy and direct patient care channels, as well as the global life science industry. Schülke is headquartered in Norderstedt, Germany, employs approximately 1,200 people, and generates sales in more than 80 countries with market leading positions in Central and Eastern Europe, Australia and Brazil. 

EQT Private Equity acquired Schülke in July 2020 with a vision to focus the business portfolio, accelerate growth in core markets, invest in sustainability and innovation, and expand its geographical footprint. Together with the Schülke management team, EQT Private Equity has delivered on this vision. Schülke repositioned to focus entirely on the healthcare and life science market, which included the sale of the Personal Care business and the discontinuation of other non-healthcare related operations. It also expanded its geographical footprint to Northern and Southern Europe and established a direct patient care channel through acquisitions, while investing in innovation including next generation products. As a result, during EQT Private Equity's ownership Schülke has delivered double digit annual revenue growth and almost doubled EBITDA in its core healthcare business.